Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian Schlain, Denise Campagnolo, Shibeshih Belachew, Barry Ticho, Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian Schlain, Denise Campagnolo, Shibeshih Belachew, Barry Ticho
Abstract
Objective: The increased risk of progressive multifocal leukoencephalopathy (PML) with natalizumab treatment is associated with the presence of anti-JC virus (JCV) antibodies. We analyzed whether anti-JCV antibody levels, measured as index, may further define PML risk in seropositive patients.
Methods: The association between serum or plasma anti-JCV antibody levels and PML risk was examined in anti-JCV antibody-positive multiple sclerosis (MS) patients from natalizumab clinical studies and postmarketing sources. For PML and non-PML patients, the probabilities of having an index below and above a range of anti-JCV antibody index thresholds were calculated using all available data and applied to the PML risk stratification algorithm. Longitudinal stability of anti-JCV antibody index was also evaluated.
Results: Anti-JCV antibody index data were available for serum/plasma samples collected >6 months prior to PML diagnosis from 71 natalizumab-treated PML patients and 2,522 non-PML anti-JCV antibody-positive patients. In patients with no prior immunosuppressant use, anti-JCV antibody index distribution was significantly higher in PML patients than in non-PML patients (p < 0.0001). Among patients who were anti-JCV antibody negative at baseline in the AFFIRM and STRATIFY-1 trials, 97% remained consistently negative or below an index threshold of 1.5 over 18 months. Retrospective analyses of pre-PML samples collected longitudinally from PML patients displayed sustained higher anti-JCV antibody index over time.
Interpretation: Anti-JCV antibody levels in serum/plasma, measured as index, may differentiate PML risk in anti-JCV antibody-positive MS patients with no prior immunosuppressant use. Continued evaluation of anti-JCV antibody index and PML risk is warranted.
© 2014 Biogen Idec. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
Figures
References
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
- O'Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83:78–86.
- Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014 Feb 14 [Epub ahead of print]
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
- Biogen Idec. Medical information website. Available at: . Accessed September 2012 to August 30, 2014.
- Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2. Neurology. 2012;78:S41. [Meeting Abstracts 1]: .002.
- Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742–750.
- Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler. 2013;19:1533–1538.
- Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol. 2012;259:2293–2298.
- Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78:1736–1742.
- Plavina T, Lee S, Berman M, et al. Longitudinal stability of anti-JC virus antibody status in multiple sclerosis patients: results of STRATIFY-1. Neurology. 2013;80:S30. 001.
- Lee P, Plavina T, Castro A, et al. A second generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57:141–146.
- Bohl DL, Brennana DC, Ryschkewitschc C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol. 2008;43:184–189.
- Pastrana DV, Wieland U, Silling S, et al. Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer. Med Microbiol Immunol. 2012;201:17–23.
- Touzé A, Le Bidre E, Laude H, et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Oncol. 2011;29:1612–1619.
- Plavina T, Subramanyam M, Bloomgren G, et al. JCV antibody index stratifies PML risk in natalizumab-treated MS patients. Available at: . Accessed November 25, 2013.
- Plavina T, Subramanyam M, Bloomgren G, et al. Use of anti-JC virus antibody index to further define risk of PML in anti-JCV antibody-positive natalizumab-treated patients with MS (0228). Presented at: 23rd Annual Meeting of the European Neurological Society; June 8–11, 2013; Barcelona, Spain.
- Focus Diagnostics. STRATIFY JCV DxSelect™ prescribing information. 2013. Available at: . Accessed November 25, 2013.
- Randhawa PS, Gupta G, Vats A, et al. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol. 2006;13:1057–1063.
- Besson C, Amiel C, Le-Pendeven C, et al. Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin's lymphoma patients and their relatives. J Clin Microbiol. 2006;44:47–50.
- Drouet E, Brousset P, Fares F, et al. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol. 1999;57:383–389.
- Stevens SJ, Blank BS, Smits PH, et al. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS. 2002;16:993–1001.
- Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med. 2008;205:841–852.
- Randhawa P, Zygmunt D, Shapiro R, et al. Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int. 2003;64:743–747.
- Olsen GH, Andresen PA, Hilmarsen HT, et al. Genetic variability in BK virus regulatory regions in urine and kidney biopsies from renal transplant patients. J Med Virol. 2006;78:384–393.
- Nakamichi K, Kishida S, Tanaka K, et al. Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Arch Virol. 2013;158:639–650.
- Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535–551.
- Masutani K, Ninomiya T, Randhawa P. HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia. Nephrol Dial Transplant. 2013;28:3119–3126.
- Outteryck O, Zéphir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. 2014;20:822–829.
- Van Pesch V, Algoed L, Boucquey D, et al. Use of the JC virus stratify assay in a cohort of natalizumab-treated patients from Belgium. Comparative results between 2011 and 2012. Presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 2–5, 2013; Copenhagen, Denmark.
- Berger JR, Houff SA, Gurwell J, et al. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74:84–90.
- Major EO, Frohman E, Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med. 2013;368:2240–2241.
- Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84:1199–1205.
- Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295–303.
- Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:1–7.
- Muñoz-Culla M, Irizar H, Castillo-Triviño T, et al. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler. 2014 May 22 [Epub ahead of print]
Source: PubMed